Thomas W. McLean

Dr. Thomas W. McLean


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Pediatrics
Verified
Journal Article
Closed access
PDF file
TRThomas B. Russell
Thomas B. Russell
EREmily K. Rinker
Emily K. Rinker
CDClaire S. Dillingham
Claire S. Dillingham
LGLaurence B. Givner
Laurence B. Givner
TMThomas W. McLean
Thomas W. McLean
Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon. We report the case of a child with kaposiform hemangioendothelioma and the Kasabach-Merritt phenomenon who developed Pneumocystis carinii pneumonia (PCP) while on sirolimus and a prednisolone taper, after lack of adequate response to prednisolone, propranolol, and vincristine. He had a prompt positive clinical and laboratory response to sirolimus, but 4 weeks after starting it, at the age of 4 months, he developed PCP. This led to respiratory failure, which required extracorporeal membrane oxygenation. Sirolimus was temporarily discontinued, and he was successfully treated for PCP with sulfamethoxazole-trimethoprim and methylprednisolone. He was restarted on sirolimus 3 weeks after discharge and given sulfamethoxazole-trimethoprim prophylaxis. At the age of 22 months, while still on sirolimus, the lesion continued to improve with test results revealing stable hemoglobin and platelet counts. PCP is a rare but life-threatening side effect of sirolimus therapy, especially in the setting of concurrent steroid treatment. Pneumocystis prophylaxis should be considered for patients receiving sirolimus.

10 December 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ABAlexandra Borst
Alexandra Borst
WEWhitney Eng
Whitney Eng
MGMorgan Griffin
Morgan Griffin
KRKiersten W. Ricci
Kiersten W. Ricci
EEElissa Engel
Elissa Engel
MJMichael R. Jeng
Michael R. Jeng

29 December 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KPKristy S. Pahl
Kristy S. Pahl
TMThomas W. McLean
Thomas W. McLean
Infantile hemangiomas (IHs) are common vascular lesions which are benign but can cause significant functional and cosmetic morbidity. Since the fortuitous discovery of propranolol being effective to treat IH over a decade ago, the therapy and prognosis for children with IH have improved dramatically. Oral propranolol (as well as other oral beta-blockers and topical timolol) are safe and effective treatments, and have now supplanted other therapies. Making the correct diagnosis is crucial, because other vascular lesions can mimic IH. In addition, IH can be the first manifestation of an underlying syndrome. For IH requiring treatment, initiating treatment early is key to optimizing success. Therefore, early recognition and referral, if necessary, are important. Continued research on IH, both basic science and clinical, should result in continued advances.

17 November 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TMThomas W. McLean
Thomas W. McLean
RSRyan Michael Stewart
Ryan Michael Stewart
TCThomas Patrick Curley
Thomas Patrick Curley
MDMark Young Dewsnup
Mark Young Dewsnup
STSydney Gillian Thomas
Sydney Gillian Thomas
JTJanet Austin Tooze
Janet Austin Tooze

18 December 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LDL. Lee Dupuis
L. Lee Dupuis
RTRoy N. Tamura
Roy N. Tamura
KKKara M. Kelly
Kara M. Kelly
JKJeffrey P. Krischer
Jeffrey P. Krischer
ALAnne‐Marie Langevin
Anne‐Marie Langevin
TMThomas W. McLean
Thomas W. McLean

3 March 2022 in Pediatric Dermatology
Verified
Journal Article
Closed access
JGJorie E. Gatts
Jorie E. Gatts
MRMarie C. Rush
Marie C. Rush
JCJennifer F. Check
Jennifer F. Check
DSDiane M. Samelak
Diane M. Samelak
TMThomas W. McLean
Thomas W. McLean